Russell Investments Group Ltd. Buys 3,234 Shares of PetIQ, Inc. (NASDAQ:PETQ)

Russell Investments Group Ltd. lifted its stake in shares of PetIQ, Inc. (NASDAQ:PETQ) by 2.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,703 shares of the company’s stock after buying an additional 3,234 shares during the period. Russell Investments Group Ltd. owned about 0.41% of PetIQ worth $1,369,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Jump Financial LLC acquired a new position in shares of PetIQ during the first quarter worth $345,000. Federated Hermes Inc. acquired a new position in shares of PetIQ during the first quarter worth $139,000. Los Angeles Capital Management LLC lifted its holdings in shares of PetIQ by 17.3% during the first quarter. Los Angeles Capital Management LLC now owns 33,886 shares of the company’s stock worth $388,000 after purchasing an additional 4,991 shares during the period. Premier Fund Managers Ltd acquired a new position in shares of PetIQ during the fourth quarter worth $3,414,000. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of PetIQ by 12.0% during the fourth quarter. Gamco Investors INC. ET AL now owns 91,579 shares of the company’s stock worth $844,000 after purchasing an additional 9,816 shares during the period. 88.57% of the stock is currently owned by institutional investors and hedge funds.

PetIQ Trading Down 0.5 %

PETQ opened at $19.70 on Wednesday. PetIQ, Inc. has a twelve month low of $6.66 and a twelve month high of $20.86. The company has a quick ratio of 1.46, a current ratio of 2.20 and a debt-to-equity ratio of 1.87. The company has a fifty day moving average of $16.95 and a 200-day moving average of $13.71. The stock has a market cap of $579.61 million, a PE ratio of -15.39, a price-to-earnings-growth ratio of 4.98 and a beta of 2.01.

PetIQ (NASDAQ:PETQ) last announced its earnings results on Tuesday, August 8th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.18 by $0.19. PetIQ had a positive return on equity of 8.53% and a negative net margin of 3.68%. The company had revenue of $314.55 million for the quarter, compared to analyst estimates of $274.19 million. On average, sell-side analysts predict that PetIQ, Inc. will post 0.5 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Benchmark reiterated a “buy” rating and set a $30.00 price target on shares of PetIQ in a report on Tuesday, August 15th. Truist Financial raised their price objective on PetIQ from $20.00 to $25.00 in a research report on Wednesday, August 9th.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.